ES2538282B1 - IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments - Google Patents

IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments Download PDF

Info

Publication number
ES2538282B1
ES2538282B1 ES201301196A ES201301196A ES2538282B1 ES 2538282 B1 ES2538282 B1 ES 2538282B1 ES 201301196 A ES201301196 A ES 201301196A ES 201301196 A ES201301196 A ES 201301196A ES 2538282 B1 ES2538282 B1 ES 2538282B1
Authority
ES
Spain
Prior art keywords
cell line
mdr
new
search
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201301196A
Other languages
Spanish (es)
Other versions
ES2538282A1 (en
Inventor
Elena MARTÍN-OROZCO SANTIAGO
David CEREZO FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Murcia
Original Assignee
Universidad de Murcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Murcia filed Critical Universidad de Murcia
Priority to ES201301196A priority Critical patent/ES2538282B1/en
Publication of ES2538282A1 publication Critical patent/ES2538282A1/en
Application granted granted Critical
Publication of ES2538282B1 publication Critical patent/ES2538282B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Línea celular tumoral resistente a fármacos IM-9R y su empleo en la búsqueda de nuevos tratamientos anti-tumorales.#IM-9R es una línea celular resistente a fármacos que expresa la proteína MDR-1 y que tiene capacidad extrusora de fármacos. Además, presenta sensibilidad colateral a hipotermia y un perfil de expresión de proteínas Bcl-2 asociado con fenotipo MDR. Dicha línea permitirá la puesta a punto de nuevas terapias dirigidas al tratamiento de tumores quimio-resistentes y posibilitará el diseño de test predictivos de respuesta a fármacos que permitan analizar nuevas moléculas y sus combinaciones para el tratamiento personalizado de los pacientes con procesos neoplásicos. Adicionalmente, la línea IM-9R permitirá identificar moléculas de señalización intracelular implicadas en el proceso de sensibilidad colateral a hipotermia, las cuales podrían constituir nuevas dianas terapéuticas en el tratamiento de tumores MDR. Finalmente, dicha línea celular posibilitará la identificación de inhibidores de MDR-1 y de proteínas Bcl-2, como Mcl-1.IM-9R drug-resistant tumor cell line and its use in the search for new anti-tumor treatments. # IM-9R is a drug-resistant cell line that expresses the MDR-1 protein and that has the ability to extrude drugs. In addition, it presents collateral sensitivity to hypothermia and a Bcl-2 protein expression profile associated with the MDR phenotype. This line will allow the development of new therapies aimed at the treatment of chemo-resistant tumors and will enable the design of predictive drug response tests that allow the analysis of new molecules and their combinations for the personalized treatment of patients with neoplastic processes. Additionally, the IM-9R line will identify intracellular signaling molecules involved in the process of collateral sensitivity to hypothermia, which could constitute new therapeutic targets in the treatment of MDR tumors. Finally, said cell line will enable the identification of MDR-1 inhibitors and Bcl-2 proteins, such as Mcl-1.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

Claims (1)

imagen1image 1
ES201301196A 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments Active ES2538282B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201301196A ES2538282B1 (en) 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201301196A ES2538282B1 (en) 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments

Publications (2)

Publication Number Publication Date
ES2538282A1 ES2538282A1 (en) 2015-06-18
ES2538282B1 true ES2538282B1 (en) 2016-05-09

Family

ID=53379961

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201301196A Active ES2538282B1 (en) 2013-12-18 2013-12-18 IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments

Country Status (1)

Country Link
ES (1) ES2538282B1 (en)

Also Published As

Publication number Publication date
ES2538282A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
CL2017001364A1 (en) New substituted indazoles, procedures for their preparation, pharmaceutical preparations containing them, as well as their use for the preparation of medicines.
BR112017026467A2 (en) use of exosomes to treat disease
CL2018003438A1 (en) Alpha-synuclein antibodies and uses thereof.
CO2019005842A2 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112016017986A2 (en) isolated antibodies, isolated nucleic acid, host cell, methods of producing an antibody, treating cancer, treating a disease and detecting human jagged1 in a biological sample, immunoconjugate, pharmaceutical formulation and antibody use
EA201892635A1 (en) IMMUNODULATORS FOR PET VISUALIZATION
DOP2016000283A (en) ANTI-RNF43 NEW NOVELS AND METHODS FOR USE
CO2019009586A2 (en) Anti-gitr antibodies and methods of using them
EA201892265A1 (en) METHODS OF TREATMENT OF OPHTHALMIC DISEASES
CO2019008675A2 (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
BR112017004883A2 (en) rgma fragment-based diagnostic assay
ES2540151A1 (en) Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use (Machine-translation by Google Translate, not legally binding)
EA201692402A1 (en) MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE
ES2538282B1 (en) IM-9R drug resistant tumor cell line and its use in the search for new anti-tumor treatments
BR112019006422A2 (en) monoclonal antibody against fzd10 and use of it
Haketa et al. Association between SIRT2 gene polymorphism and height in healthy, elderly Japanese subjects
EA201692432A1 (en) METHOD AND DEVICE FOR DETERMINING THE TIME OF DISAPPEABILITY OF FILM MEDICINE FORM
EA201692013A1 (en) NEW APPLICATION N, N-BIS-2-MERCAPTOETHYL-ISOPHTHALAMIDE
IT201700066486A1 (en) Blood serum for use in the treatment of ophthalmological neurodegenerative diseases
ES2482468B1 (en) Method of obtaining useful data for differential diagnosis of lung cancer
ES2464440B2 (en) Spectroscopic method for the determination of proteins in complex media.
Khungar et al. Cirrhosis with refractory ascites: serial large volume paracentesis, TIPS, or transplantation?
ES2560902A2 (en) Method for determining degree of modified potency of a medicament
Diomedi et al. Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on" CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al
SG11202111473UA (en) Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2538282

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160509